In Russia, most CNS clinical studies have been conducted in MS, epilepsy, AD, stroke, depression and schizophrenia. A number of leading Russian biopharmaceutical companies and life science institutional investors are engaged in the development of new disease-modifying therapies in these areas and are actively seeking regional in-licensing and partnering opportunities with foreign drug developers – especially in biologics. Ekaterina Mochalova of Global Clinical Trials (GCT) explores the huge potential of the region to contribute to international clinical research.